About G2/mitotic-specific cyclin-B1
G2/mitotic-specific cyclin-B1 (CCNB1) is a protein
from Homo sapiens identified by UniProt accession
P14635, 433 residues long.
MolForge cross-references it against 0 known binders and
418 disease associations.
Target properties
| Protein name | G2/mitotic-specific cyclin-B1 |
| UniProt accession | P14635 |
| Gene | CCNB1 |
| Organism | Homo sapiens |
| Length | 433 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (418)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.30
- lung adenocarcinoma · score 0.30
- endometrial cancer · score 0.29
- breast adenocarcinoma · score 0.28
- head and neck squamous cell carcinoma · score 0.28
- esophageal cancer · score 0.27
- squamous cell lung carcinoma · score 0.25
- hepatocellular carcinoma · score 0.13
- neoplasm · score 0.11
- protein measurement · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P14635-F1 | alphafold | PREDICTED | 76.55 | — |
Amino-acid sequence (433 residues)
MALRVTRNSK INAENKAKIN MAGAKRVPTA PAATSKPGLR PRTALGDIGN KVSEQLQAKM PMKKEAKPSA TGKVIDKKLP KPLEKVPMLV PVPVSEPVPE PEPEPEPEPV KEEKLSPEPI LVDTASPSPM ETSGCAPAEE DLCQAFSDVI LAVNDVDAED GADPNLCSEY VKDIYAYLRQ LEEEQAVRPK YLLGREVTGN MRAILIDWLV QVQMKFRLLQ ETMYMTVSII DRFMQNNCVP KKMLQLVGVT AMFIASKYEE MYPPEIGDFA FVTDNTYTKH QIRQMEMKIL RALNFGLGRP LPLHFLRRAS KIGEVDVEQH TLAKYLMELT MLDYDMVHFP PSQIAAGAFC LALKILDNGE WTPTLQHYLS YTEESLLPVM QHLAKNVVMV NQGLTKHMTV KNKYATSKHA KISTLPQLNS ALVQDLAKAV AKV
Explore G2/mitotic-specific cyclin-B1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets